Literature DB >> 27488441

MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Keiko Mizuno1, Hiroko Mataki1, Naohiko Seki2, Tomohiro Kumamoto1, Kazuto Kamikawaji1, Hiromasa Inoue1.   

Abstract

In spite of advances in the diagnosis and current molecular target therapies of lung cancer, this disease remains the most common cause of cancer-related death worldwide. Approximately 80% of lung cancers is non-small cell lung cancer (NSCLC), and 5-year survival rate of the disease is ~20%. On the other hand, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology. IPF is refractory to treatment and has a very low survival rate. Moreover, IPF is frequently associated with lung cancer. However, the common mechanisms shared by these two diseases remain poorly understood. In the post-genome sequence era, the discovery of noncoding RNAs, particularly microRNAs (miRNAs), has had a major impact on most biomedical fields, and these small molecules have been shown to contribute to the pathogenesis of NSCLC and IPF. Investigation of novel RNA networks mediated by miRNAs has improved our understanding of the molecular mechanisms of these diseases. This review summarizes our current knowledge on aberrantly expressed miRNAs regulating NSCLC and IPF based on miRNA expression signatures.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27488441     DOI: 10.1038/jhg.2016.98

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  147 in total

Review 1.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.

Authors:  A L Katzenstein; J L Myers
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

2.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.

Authors:  Marco Chilosi; Venerino Poletti; Alberto Zamò; Maurizio Lestani; Licia Montagna; Paola Piccoli; Serena Pedron; Manuela Bertaso; Aldo Scarpa; Bruno Murer; Alessandra Cancellieri; Roberta Maestro; Gianpietro Semenzato; Claudio Doglioni
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

3.  Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.

Authors:  Paul K Paik; Anna M Varghese; Camelia S Sima; Andre L Moreira; Marc Ladanyi; Mark G Kris; Natasha Rekhtman
Journal:  Mol Cancer Ther       Date:  2012-08-14       Impact factor: 6.261

Review 4.  Functional significance of aberrantly expressed microRNAs in prostate cancer.

Authors:  Yusuke Goto; Akira Kurozumi; Hideki Enokida; Tomohiko Ichikawa; Naohiko Seki
Journal:  Int J Urol       Date:  2015-01-20       Impact factor: 3.369

5.  Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution.

Authors:  C Arden Pope; Richard T Burnett; Michael J Thun; Eugenia E Calle; Daniel Krewski; Kazuhiko Ito; George D Thurston
Journal:  JAMA       Date:  2002-03-06       Impact factor: 56.272

6.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

7.  Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells.

Authors:  C Quintavalle; E Donnarumma; M Iaboni; G Roscigno; M Garofalo; G Romano; D Fiore; P De Marinis; C M Croce; G Condorelli
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

8.  Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.

Authors:  Yoshimasa Saito; Jeffrey M Friedman; Yoshitomo Chihara; Gerda Egger; Jody C Chuang; Gangning Liang
Journal:  Biochem Biophys Res Commun       Date:  2008-12-29       Impact factor: 3.322

9.  Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma.

Authors:  Keiko Mizuno; Naohiko Seki; Hiroko Mataki; Ryosuke Matsushita; Kazuto Kamikawaji; Tomohiro Kumamoto; Koichi Takagi; Yusuke Goto; Rika Nishikawa; Mayuko Kato; Hideki Enokida; Masayuki Nakagawa; Hiromasa Inoue
Journal:  Int J Oncol       Date:  2015-12-14       Impact factor: 5.650

10.  Epigenetic silencing of miR-145-5p contributes to brain metastasis.

Authors:  Sara Donzelli; Federica Mori; Teresa Bellissimo; Andrea Sacconi; Beatrice Casini; Tania Frixa; Giuseppe Roscilli; Luigi Aurisicchio; Francesco Facciolo; Alfredo Pompili; Maria Antonia Carosi; Edoardo Pescarmona; Oreste Segatto; Greg Pond; Paola Muti; Stefano Telera; Sabrina Strano; Yosef Yarden; Giovanni Blandino
Journal:  Oncotarget       Date:  2015-11-03
View more
  26 in total

1.  MicroRNA-192 inhibits the proliferation, migration and invasion of osteosarcoma cells and promotes apoptosis by targeting matrix metalloproteinase-11.

Authors:  Guowei Shang; Yang Mi; Yingwu Mei; Guanghui Wang; Yadong Wang; Xinjie Li; Yisheng Wang; Yuebai Li; Guoqiang Zhao
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

2.  The lncRNA H19 Mediates Pulmonary Fibrosis by Regulating the miR-196a/COL1A1 Axis.

Authors:  Qingchun Lu; Zhongliang Guo; Wang Xie; Wenjing Jin; Dongyi Zhu; Song Chen; Tao Ren
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

3.  Quantitative proteomic analysis of the miR-148a-associated mechanisms of metastasis in non-small cell lung cancer.

Authors:  Dandan Chu; Jing Li; Hechun Lin; Xiao Zhang; Hongyu Pan; Lei Liu; Tao Yu; Mingxia Yan; Ming Yao
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

4.  Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.

Authors:  Peiyan Zheng; Shixue Sun; Jingxian Wang; Xiaohua Douglas Zhang; Baoqing Sun; Zhangkai Jason Cheng; Kuan Cheok Lei; Mingshan Xue; Teng Zhang; Huimin Huang
Journal:  Cell Mol Life Sci       Date:  2022-01-11       Impact factor: 9.261

5.  MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Authors:  Harinath Bahudhanapati; Jiangning Tan; Justin A Dutta; Stephen B Strock; John Sembrat; Diana Àlvarez; Mauricio Rojas; Benedikt Jäger; Antje Prasse; Yingze Zhang; Daniel J Kass
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

6.  MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression.

Authors:  Cun Gao; Rui Dong; Yongmeng Li; Jinghui Liang; Hui Tian
Journal:  Oncol Lett       Date:  2021-05-17       Impact factor: 2.967

7.  TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis.

Authors:  Zhicheng Huang; Shuangyan Sun; Changliang Yang; Jun Zheng; Yingji Nan; Ruikun Zhao; Zhiguo Lang; Hang Li; Lixia Ma
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

8.  p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA-320a in lung cancer.

Authors:  Aimin Xing; Li Pan; Jingzhen Gao
Journal:  Thorac Cancer       Date:  2017-11-21       Impact factor: 3.500

9.  The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster.

Authors:  Keiichi Yonemori; Naohiko Seki; Tetsuya Idichi; Hiroshi Kurahara; Yusaku Osako; Keiichi Koshizuka; Takayuki Arai; Atsushi Okato; Yoshiaki Kita; Takaaki Arigami; Yuko Mataki; Yuko Kijima; Kosei Maemura; Shoji Natsugoe
Journal:  Oncotarget       Date:  2017-07-26

10.  An alternative microRNA-mediated post-transcriptional regulation of GADD45A by p53 in human non-small-cell lung cancer cells.

Authors:  Jie Li; Jie Dong; Shaohua Li; Wei Xia; Xueting Su; Xingliang Qin; Ying Chen; Hongmei Ding; Hui Li; Aixue Huang; Chenjun Bai; Tongnan Hu; Chenglong Wang; Bingfeng Chu; Ningsheng Shao
Journal:  Sci Rep       Date:  2017-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.